

PATENT  
Atty. Docket No.: RBN-001DV  
(9199/2)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Keene *et al.*

SERIAL NUMBER: Not yet assigned      GROUP NUMBER: Not yet assigned

FILING DATE: Herewith      EXAMINER: Not yet assigned

TITLE: Methods for Isolating and Characterizing Endogenous mRNA-Protein (mRNP) Complexes

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**PRELIMINARY AMENDMENT**

Sir:

This application is a divisional of U.S. Serial No. 09/750,401, filed December 28, 2000.

**AMENDMENT**

**In the Specification**

Please replace Table 2 on pages 30-31 with the following. A marked-up version of the amended table is attached at the end of this Amendment.

**TABLE 2**

Gene	#UTR Consensus Sequence
CD44	AUUUUCUAUUCUUU <u>UUUAUUU</u> UAUGUCAUUUUUUUA [SEQ ID NO: 1] UAAAAAACCAA <u>UUUGAUU</u> GGCUCUAAACA [SEQ ID NO: 2]
IGF-2	UAAAGAA <u>AUUAAU</u> GGCUAAAAACAUA [SEQ ID NO: 3] CUAAAA <u>AUUAAU</u> GGCUAAAAAA [SEQ ID NO: 4] UCACUCUU <u>AUUUUU</u> AU [SEQ ID NO: 5]
HOX 2.5	AAAU <u>UUUAUU</u> AGUUA [SEQ ID NO: 6] AUCAGG <u>UUCUUU</u> UGGUUGU [SEQ ID NO: 7]
Inhibitor	AU <u>UUUAUC</u> GUUA [SEQ ID NO: 8]
J6	UUUUGUUUUUCUCCUUUU <u>UUAGUU</u> UUUCAA [SEQ ID NO: 9]
GADD45	UAUUUUUUUCUUUUUUUU <u>UUUUGGU</u> CUUUAU [SEQ ID NO: 10] UUAAAUUCUCAGAAGU <u>UUUAUU</u> AUAAUCUU [SEQ ID NO: 11]
Nexin 1	UUCUGUUAAAUUU <u>UUUAUU</u> ACUGCUUUUUUUU [SEQ ID NO: 12] AUUUUAUAGUAGUU <u>UUUAUGU</u> UUUUAUGGAAAA [SEQ ID NO: 13] AUUUGCCUU <u>UUUAAU</u> CUUUUU [SEQ ID NO: 14]
Egr-1	UAUUUUGUGGU <u>UUUAUUU</u> ACUUUGUACUU [SEQ ID NO: 15]
Zif268	U <u>UUUGUU</u> UCCUU [SEQ ID NO: 16] UUU <u>UUUAUUU</u> UCUGUAUUUUUU [SEQ ID NO: 17]
Neuronal- Cadherin	UUUUUUUUAAAUUUU <u>UUUAUUU</u> UCUUUUU [SEQ ID NO: 18] UUUUUUAUUUUC <u>UGUAUUU</u> UUU [SEQ ID NO: 19] UUUUUAAUUU <u>UUUAAU</u> UUUUUU [SEQ ID NO: 20]
Integrin alpha	AAUGG <u>UUUAUAU</u> UUAUGAU [SEQ ID NO: 21]
5	UUG <u>UUUAUAU</u> CUUCAU [SEQ ID NO: 22]
SEF2	UUCAAGCGC <u>UGANUU</u> [SEQ ID NO: 23]
Cf2r	UGCAUCGAUCCG <u>UGAUUU</u> ACUACU [SEQ ID NO: 24]
Integrin	UAUAAUUU <u>UUAAUUU</u> UUUAUUAUUUU [SEQ ID NO: 25]
Beta	UUAAUUUACCUUUUUUUUUUUC <u>UUUAAU</u> CCUGGU [SEQ ID NO: 26]
CTCF	UUAUGAAUGU <u>UAUAUUU</u> GU [SEQ ID NO: 27] UC <u>UUAAUUU</u> UUUCUCUUUUUUUUUCUUU [SEQ ID NO: 28] UUUUUUUUUCCU <u>UUUAAU</u> GUAAAUGGUUCUUU [SEQ ID NO: 29]
TGF beta 2	UUAAUGAUCAUUCAGAUUGUA <u>UAUAUUU</u> GUUCCUUU [SEQ ID NO: 30] UUCAAUUUUU <u>UUUAUAU</u> ACUAUCUU [SEQ ID NO: 31] UUUUUC-- <u>UUUAAU</u> UGGUUUUUUU [SEQ ID NO: 32]
MTP	UGUCUUGUCUGAGCA <u>UUUAUUU</u> UCAA [SEQ ID NO: 33] UUCUCGUCUUG <u>UUUAUUU</u> UACAA [SEQ ID NO: 34] UAUAUAUAUAG <u>UUUAUGU</u> UUUGGAUGUUUGGU [SEQ ID NO: 35]
Cyclin D2	AUGUCUUGUUCUU <u>UGUGUUU</u> UUAGGAU [SEQ ID NO: 36] (AU/GA) <u>UUUAUUU</u> (UA/AG) [SEQ ID NO: 37]
<i>In Vitro Consensus Sequence</i>	